Edwards Lifesciences Co. (NYSE:EW - Get Free Report) CFO Scott B. Ullem sold 7,250 shares of the firm's stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $85.80, for a total transaction of $622,050.00. Following the sale, the chief financial officer now owns 19,074 shares in the company, valued at $1,636,549.20. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Edwards Lifesciences Price Performance
NYSE:EW opened at $84.68 on Wednesday. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The firm has a fifty day simple moving average of $90.23 and a 200 day simple moving average of $79.16. The stock has a market capitalization of $50.97 billion, a PE ratio of 36.50, a P/E/G ratio of 4.28 and a beta of 1.05.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The firm had revenue of $1.60 billion during the quarter, compared to analysts' expectations of $1.58 billion. On average, research analysts expect that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.
Hedge Funds Weigh In On Edwards Lifesciences
What President Biden's new law means for investors
From Stansberry Research | Ad
What's Got Musk, Bezos, and Gates So Excited?
Billionaires are plowing millions of dollars into a new technology that early estimates say could generate more wealth than A.I. – and determine the future of companies like Microsoft. The problem? Most investors have no idea it's happening, or how to profit on it.
This expert just went public with all the details, including which stocks to jump on immediately.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EW. Vanguard Group Inc. lifted its holdings in shares of Edwards Lifesciences by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 52,363,400 shares of the medical research company's stock worth $3,992,709,000 after buying an additional 729,984 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Edwards Lifesciences by 9.5% during the first quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company's stock worth $1,813,089,000 after buying an additional 1,644,869 shares in the last quarter. Brown Advisory Inc. lifted its holdings in shares of Edwards Lifesciences by 20.1% during the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company's stock worth $1,386,333,000 after buying an additional 3,048,274 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Edwards Lifesciences by 2.4% during the fourth quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company's stock worth $1,283,098,000 after buying an additional 393,109 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $648,540,000. 79.46% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
EW has been the subject of several research reports. Wells Fargo & Company raised their price target on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the stock an "overweight" rating in a research note on Friday, April 26th. StockNews.com raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Monday. Piper Sandler raised their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a "neutral" rating in a research note on Friday, April 26th. Oppenheimer raised their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an "outperform" rating in a research note on Monday, March 18th. Finally, Stifel Nicolaus raised their price target on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a "hold" rating in a research note on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $92.71.
Check Out Our Latest Research Report on EW
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
